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F O L L O W U P R E S U L T S OF A COMBINATION OF C A L C I T O N I N G E N E -
R E L A T E D P E P T I D E AND P R O S T A G L A N D I N E l IN T H E 
T R E A T M E N T OF E R E C T I L E D Y S F U N C T I O N 
M O H A M A D D J A M I L I A N , C H R I S T I A N G. STIEF, M A R K U S K U C Z Y K A N D UDO JONAS 
From the Department of Urology, Medizinische Hochschule Hannover Medical School, Hannover, Germany 
A B S T R A C T 
Recent human and animal studies have shown a possible role for calcitonin gene-related peptide 
in penile erection and a therapeutic benefit in combination wi th prostaglandin E l for autoinjection 
therapy. The ethical committee approved calcitonin gene-related peptide-prostaglandin E l combi­
nation for cases of nonresponse or cavernous fibrosis to papaverine-phentolamine. Since June 1990, 
65 patients (59 nonresponders and 6 wi th fibrosis) were injected wi th 5 ^g. calcitonin gene-related 
peptide plus 10 μg. prostaglandin E l . Of the 59 nonresponders to papaverine-phentolamine 31 and 
of the 6 patients wi th fibrosis 5 had ful l erectile response. Of these 36 patients 2 experienced pain 
during the pharmacologically induced erection. A total of 39 patients who had had at least 20 
autoinjections of calcitonin gene-related peptide plus prostaglandin E l was available for minimum 
followup. There were no side effects, such as pain (the 2 patients w i t h pain mentioned previously 
were not included in the autoinjection therapy group), systemic side effects or (increased) fibrosis. 
Our results show that a combination of calcitonin gene-related peptide and prostaglandin E l may 
be beneficial to the treatment of impotence in carefully selected patients. 
K E Y W O R D S : impotence, penile erection, prostaglandins E , calcitonin gene-related peptide 
Since the identification of the neurotransmitters for penile 
erection would have significant impact on the treatment of 
erectile dysfunction, research has focused on this topic of 
pharmaco-mechanical coupling during the last several years.1"7 
Recently, endothelial derived relaxing factor has been shown 
to participate in cavernous smooth muscle relaxation. 8 1 2 The 
classical drugs (papaverine, papaverine plus phentolamine and 
prostaglandin El ) for autoinjection therapy induce a full erec­
tile response in about 50 to 70% of an unselected population of 
men with erectile dysfunction.13"21 The remaining patients with 
erectile dysfunction cannot be treated by autoinjection, al­
though they would fit into its selection criteria and be willing 
to accept this therapeutic option. Therefore, a new drug for 
intracavernous injection with a higher response rate is needed, 
at least for the latter patients. Previous studies have shown the 
combination of prostaglandin E l with calcitonin gene-related 
peptide for intracavernous injection to be more effective in 
inducing an erectile response than papaverine plus phentol­
amine or prostaglandin E l alone.22 Therefore, we offered pa­
tients not responding to papaverine plus phentolamine with a 
sufficient erectile response or those with cavernous fibrosis 
during such therapy a combination of 5 μg. calcitonin gene-
related peptide plus 10 prostaglandin E l . Our followup data 
are reported. 
P A T I E N T S A N D M E T H O D S 
At our impotence clinic all patients undergo a comprehensive 
noninvasive or semi-invasive diagnostic evaluation. Since we 
routinely use intracavernous injections of vasoactive drugs for 
this evaluation, patients with stages I I I and IV arterial occlusive 
disease, cardiac dysrhythmias, recent myocardial infarction, 
sexual deviation, severe psychogenic disorders, addiction, se­
vere liver insufficiency and age older than 65 years were ex­
cluded. Case history including a questionnaire and sexual case 
history by a psychiatrist were taken. Blood laboratory tests, 
pharmacological tests,23 single potential analysis of cavernous 
electric activity 2 4 and Doppler study 2 5 , 2 6 were performed. Phar-
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maco-cavernosometry or angiography was done as needed in 
select patients. 
Pharmacological testing was done in a relaxed atmosphere 
after the patient was informed about the method aid its pos­
sible side effects, and written informed consent was obtained. 
With the patient in the supine position, the first injection was 
given, which consisted of a low dose of 0.2 ml. of a papaverine 
(15 mg./ml.)-phentolamine (0.5 mg./ml.) mixture (correspond­
ing to 3 mg. papaverine plus 0.1 mg. phentolamine). Only 1 
injection a day was administered to prevent priapisn by addi­
tive effects, and the patient was advised to restrain from 
psychogenic or reflexogenic stimulation to allow comparison of 
the results. I f erectile response was insufficient, the dose was 
augmented to 0.5, 1 and 2 ml., respectively, for the following 
injections. I f 2 ml. (corresponding to 30 mg. papaverine plus 1 
mg. phentolamine) did not induce a full erection, the dose was 
repeated but stimulation was added. The erectile res>onse was 
evaluated by a urologist based on inspection and palpition, and 
graded as follows: E0—no response, El—slight tumescence, 
E2—medium tumescence, E3—full tumescence, E4—full tu ­
mescence with medium rigidity and E5—full erectioi. 
When the high dose of papaverine-phentolamine >lus stim­
ulation did not induce an erectile response sufficient for inter­
course, the patients were informed about the high likelihood of 
venous leakage as the etiology of the erectile dysfunttion, and 
the therapeutic options of venous surgery, penile >rosthesis 
and a trial of calcitonin gene-related peptide plus prostaglandin 
E l were presented. Marked cavernous fibrosis due to mtoinjec­
tion therapy with other drugs was the other indication for 
which the calcitonin gene-related peptide-prostaghndin E l 
combination was approved by the Ethical Commitee of the 
Medizinische Hochschule Hannover (approval No. -32). The 
patients were extensively informed about the exprimental 
nature of this drug combination and possible side effects, such 
as severe circulatory symptoms or significant cavernms fibro­
sis. They were told that the intracavernous injecion of 1 
compound (prostaglandin El ) alone may be tried bu the out­
come would probably be less effective.22 
If the patient wanted to try the combination, writtei consent 
was obtained and he was injected with 5 μg. calcitoiin gene-
1296 
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related peptide plus 10 μg. prostaglandin E l intracavernously 
in the supine position without any stimulation. When this dose 
did rot induce a full erectile response, the same amount was 
injec:ed with additional stimulation after a delay of at least 24 
hours. If the calcitonin gene-related peptide-prostaglandin E l 
mixture induced an erection sufficient for intercourse, the 
patients were trained in the handling of the procedure itself 
and advised to present immediately if a side effect occurred. 
Due ίο the experimental nature of the study, followup was done 
after every 10 autoinjections, and it included specific case 
history, physical examination, blood pressure measurement and 
blood laboratory tests. When cavernous fibrosis was suspected 
by case history or physical examination, high resolution sonog­
raphy was performed to examine the cavernous bodies. 
R E S U L T S 
From September 1988 to May 1992, 59 patients with an 
insufficient erectile response to 30 mg. papaverine plus 1 mg. 
phentolamine and stimulation, and 6 with cavernous fibrosis 
due to autoinjection therapy with papaverine-phentolamine 
selected the calcitonin gene-related peptide plus prostaglandin 
E l combination to restore erectile potency. Of the 59 nonre-
sponders to papaverine-phentolamine 33 achieved a full erec­
tion (E5), 21 an almost full erection (E4) and 5 tumescence (E2 
or E3) with calcitonin gene-related peptide-prostaglandin E l . 
Two patients with a full erectile response experienced intra-
penile pain but there were no other acute objective or subjective 
side effects. Of the 6 patients with cavernous fibrosis calcitonin 
gene-related peptide-prostaglandin E l induced a full erection 
(E5) in 5 and medium erection (E3) in 1. No acute side effects 
were observed in this group. 
Due to the inconvenience of the intracavernous injection 
itself, the insufficient erectile response or the unknown long-
term effects of this study only 34 of the 59 nonresponders and 
5 of the 6 patients with fibrosis entered the autoinjection 
program with calcitonin gene-related peptide plus prostaglan­
din E l . Of 26 patients who completed at least 20 autoinjections 
17 had dene more than 40 and 9 had done more than 80 
injections. No cavernous fibrosis or penile deviation was found 
subjectively or objectively (palpation) in any of the nonrespond­
ers, nor was there any increase in size of the fibrous area (5 
patients) or of the penile deviation (2 patients) in the fibrosis 
group. There were no significant changes in blood laboratory 
tests and no prolonged erections (duration more than 6 hours). 
D I S C U S S I O N 
Previous studies have shown the combination of calcitonin 
gene-related peptide and prostaglandin E l to be more effective 
in inducing a full erectile response than the combination of 
papaverine-phentolamine or prostaglandin E l alone.22 In our 
series the combination of 5 μg. calcitonin gene-related peptide 
and 10 Mg. prostaglandin E l induced a full erectile response in 
31 of 59 patients (53%) who had had an insufficient response 
to papave.'ine-phentolamine. Although we know that prosta­
glandin E: is somewhat more effective in inducing a full erectile 
response, vve did not routinely inject intracavernously prosta­
glandin EL alone, since the combination of calcitonin gene-
related peptide plus prostaglandin E l appeared to be signifi­
cantly mae effective. This practice is also supported by the 
53% rate >f full erections with calcitonin gene-related peptide 
plus prostaglandin E l in patients who did not respond to 
papaverine plus phentolamine. This assumption is in accord­
ance with the findings of another group working with the 
combination of calcitonin gene-related peptide plus prostaglan­
din E l bit it was used only in patients not responding to 80 
mg. papaverine plus 2 mg. phentolamine or to 40 μg. prosta­
glandin E L , with a reported success rate of 25%.27 The superior 
effectiveness of the combination of calcitonin gene-related pep­
tide plus rrostaglandin E l compared to prostaglandin E l alone, 
although he amount of prostaglandin E l in the combination 
is reduced, may be explained by the different effector mecha­
nisms of these substances. Prostaglandin E l acts via specific 
receptors on the cell surface, whereas calcitonin gene-related 
peptide relaxes smooth muscles by hyperpolarization, most 
likely induced by potassium channel opening.28 Furthermore, 
calcitonin gene-related peptide seems to stimulate the produc­
tion of cyclic adenosine monophosphate, resulting in smooth 
muscle relaxation.29 
In addition to the potentiating effect of the combination of 
calcitonin gene-related peptide plus prostaglandin E l regarding 
erectile response, a pain reducing effect of the combination 
compared to prostaglandin E l alone has been described previ­
ously. This low rate of pain during and/or after the intracav­
ernous injection was reproduced in our series with only 2 of 65 
patients (3%) experiencing pain after the injection of the com­
bination of calcitonin gene-related peptide plus prostaglandin 
E l . This 3% rate is significantly lower than the 20 to 30% rate 
after prostaglandin E l alone.13 The pain reducing effect of the 
combination of calcitonin gene-related peptide plus prostaglan­
din E l may be due to the reduction of the amount of prosta­
glandin E l in the combination compared to the application of 
prostaglandin E l alone, as well as the anti-inflammatory effect 
of calcitonin gene-related peptide itself.3 0 
The results of this clinical experimental study on patients 
with erectile dysfunction who are either not responding to 
papaverine-phentolamine or in whom cavernous fibrosis devel­
ops due to papaverine-phentolamine suggest a possible benefi­
cial effect of the combination of calcitonin gene-related peptide 
plus prostaglandin E l for intracavernous injection. Because of 
the experimental nature of our study patients should be care­
fully selected and followed closely. 
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